000			01691 a2200469 4500
005			20250514053046.0
264		0	_c20030716
008			200307s 0 0 eng d
022			_a1567-5769
024	7		_a10.1016/s1567-5769(02)00141-8 _2doi
040			_aNLM _beng _cNLM
100	1		_aJacob, C
245	0	0	_aDMSO-treated HL60 cells: a model of neutrophil-like cells mainly expressing PDE4B subtype. _h[electronic resource]
260			_bInternational immunopharmacology _cNov 2002
300			_a1647-56 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_a3',5'-Cyclic-AMP Phosphodiesterases _xantagonists & inhibitors
650	0	4	_aCell Differentiation _xdrug effects
650	0	4	_aCell Size _xdrug effects
650	0	4	_aCyclic Nucleotide Phosphodiesterases, Type 3
650	0	4	_aCyclic Nucleotide Phosphodiesterases, Type 4
650	0	4	_aDimethyl Sulfoxide _xpharmacology
650	0	4	_aDown-Regulation _xdrug effects
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aFlow Cytometry
650	0	4	_aGene Expression _xdrug effects
650	0	4	_aHL-60 Cells
650	0	4	_aHumans
650	0	4	_aIsoenzymes _xantagonists & inhibitors
650	0	4	_aNADPH Oxidases _xmetabolism
650	0	4	_aNeutrophils _xcytology
650	0	4	_aPhenotype
650	0	4	_aReceptors, IgG _xmetabolism
650	0	4	_aSuperoxides _xmetabolism
700	1		_aLeport, M
700	1		_aSzilagyi, C
700	1		_aAllen, J M
700	1		_aBertrand, C
700	1		_aLagente, V
773	0		_tInternational immunopharmacology _gvol. 2 _gno. 12 _gp. 1647-56
856	4	0	_uhttps://doi.org/10.1016/s1567-5769(02)00141-8 _zAvailable from publisher's website
999			_c12275065 _d12275065